Eribulin Mesylate (CAS: 441045-17-6) is a potent microtubule-targeting agent and synthetic analog of halichondrin B. It disrupts microtubule growth, causing cell cycle arrest and apoptosis. Eribulin is FDA-approved for treating metastatic breast cancer and liposarcoma and is also explored in antibody-drug conjugates (ADCs) for targeted cancer therapy.
Payloads and Linker modified Payloads
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.
日本语
한국어
Français
Deutsch
España
Türkiye